YOLFTbeta
Cybin Inc. Common Stock

Cybin Inc. Common Stock

HELP · NASDAQ · Healthcare / Biotechnology

8.87USD+0.01 (+0.11%)

Price History

Full chart

Market Stats

Previous Close8.86
Open8.91
Day Range8.50 – 9.06
52-Week Range3.76 – 15.15
Volume974.60K
Market Cap919.83M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.92
Dividend Yield0.00%
Beta0.63
50-Day Avg11.09
200-Day Avg7.22

About

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Eric So L.L.B.
  • Employees100
  • Headquarters100 King Street West, Toronto, ON, Canada, M5X 1C9, USA
  • Websitehttps://www.helus.com

Leadership

  • Mr. Eric So L.L.B.Co-Founder, President & Executive Chairman · b. 1976
  • Mr. Greg CaversChief Financial Officer · b. 1971
  • Mr. Aaron BartloneChief Operating Officer · b. 1967
  • Dr. Amir Inamdar FFPM, MBBSChief Medical Officer · b. 1974
  • Mr. John KanakisCo-Founder · b. 1980
  • Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer · b. 1960
  • Ms. Lori ChallengerChief Compliance, Ethics & Administrative Officer
  • Mr. Gabriel FahelChief Legal Officer & Corporate Secretary · b. 1976
  • Sara Brittany SomersetChief Communications Officers
  • Ms. Regina DonohueChief People Officer

Financials

Income Statement

Currency: USD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue----864.00K167.76K251.01K-18.15M472.27K-44.68M
Growth (%)------80.58%+49.63%-7329.95%+102.60%-9561.61%
Cost of Revenue----1.18M167.76K251.01K424.74K472.27K119.23K
Gross Profit-----311.00K-167.76K-251.01K-18.57M-472.27K-44.80M
Gross Margin-----36.00%-100.00%-100.00%102.34%-100.00%100.27%
Operating Expense----30.72M63.67M51.27M60.26M142.67M96.87M
Operating Income-127.00K-189.95K-80.52K-1.95M-31.04M-63.84M-51.52M-78.84M-143.15M-141.68M
Operating Margin-----3592.01%-38053.17%-20523.87%434.40%-30310.42%317.06%
EBITDA-127.00K-220.81K-80.91K9.60K-30.99M-63.67M-51.27M-78.41M-142.94M-141.56M
EBITDA Margin-----3586.34%-37953.03%-20423.88%432.06%-30265.74%316.79%
Net Income-127.00K-220.81K-101.00K-1.94M-32.22M-67.63M-47.49M-78.08M-113.14M-147.05M
Net Income Margin-----3729.17%-40314.14%-18919.19%430.23%-23956.00%329.09%
R&D---321.60K3.30M17.59M25.49M32.36M54.91M86.04M
R&D as % of Total Revenue----381.94%10482.83%10155.17%-178.32%11626.82%-192.54%
Interest Expense----10.00K241.00K---4.04M
Interest Expense % of Total Revenue----1.16%143.66%----9.05%

Balance Sheet

Currency: CAD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets443.08K456.18K408.38K1.71M92.11M84.06M53.90M302.02M258.62M251.98M
Total Liabilities150.29K15.93K13.65K263.00K5.99M7.91M5.66M10.10M21.42M19.44M
Total Equity292.78K440.25K394.73K1.45M86.12M76.16M48.23M291.93M237.20M232.24M
Cash432.81K433.11K314.32K1.54M64.03M53.64M16.63M208.99M135.02M157.78M
Total Debt-------291.00K--
Net Debt-432.81K-433.11K-314.32K-1.54M-64.03M-53.64M-16.63M-208.70M-135.02M-157.78M

Cash Flow

Currency: USD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow2.81K-237.03K-83.78K-1.38K-19.03M-45.21M-47.43M-68.91M-101.30M-132.42M
Investing Cash Flow-10.00K-10.00K-35.00K-170.4-1.19M-770.00K-3.31M6.92M-1.97M-1.35M
Financing Cash Flow440.00K247.32K-5.26K82.72M35.78M13.56M254.51M20.20M196.97M
Capital Expenditure10.00K10.00K35.00K0231.00K520.00K3.31M710.00K1.97M1.36M
Free Cash Flow-7.18K-247.03K-118.78K-1.38K-19.26M-45.73M-50.74M-69.62M-103.27M-133.79M
FCF to OCF-255.33%104.22%141.77%100.00%101.21%101.15%106.98%101.03%101.94%101.03%

Earnings

Report DateFeb 15, 2021Jun 28, 2021Aug 13, 2021Nov 15, 2021Feb 10, 2022Jun 22, 2022Aug 9, 2022Nov 14, 2022Feb 14, 2023Jun 28, 2023Aug 14, 2023Nov 13, 2023Feb 14, 2024Jun 25, 2024Aug 8, 2024Nov 13, 2024Feb 10, 2025Jun 30, 2025Jul 1, 2025Nov 13, 2025Feb 13, 2026Jun 29, 2026Aug 14, 2026Nov 12, 2026
EPS Estimate-0.76--1.77-3.17-3.32-3.04--2.85-2.66--2.13-1.77-1.37--1.33-0.91-1.57-1.23-1.10-1.33-0.98-1.04-0.80-0.67
EPS Actual-3.80-2.75-3.40-3.89-3.65-3.65-2.21-2.09-2.28-1.97-2.66-1.90-3.42-0.79-0.76-2.86-0.53-1.46-0.97-1.65-1.36-1.02-0.91-
Surprise-400.00%--92.09%-22.71%-9.94%-20.07%-26.67%14.29%--24.88%-7.34%-149.63%-42.86%-214.29%66.24%-18.70%11.98%-24.06%-38.78%1.92%-13.75%-
TimingAfter-hours-After-hoursPre-marketPre-marketPre-market-After-hoursPre-market-Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hoursAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap919.83M
Enterprise Value909.21M
Trailing P/E0.00
Forward P/E0.00
Price / Sales16436.36
Price / Book3.93
EPS-3.92
Book Value3.91
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-166.94M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-86.94%
Return on Assets-44.38%
Shares Outstanding73.06M
Shares Float58.56M
Beta0.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
41.26%
Insiders
14.03%
Retail / Other
44.71%

Top Institutional Holders

  • VR Adviser, LLC
    3.85M5.27%
  • Orbimed Advisors LLC
    3.83M5.25%
  • Adage Capital Partners Gp LLC
    3.06M4.19%
  • Millennium Management LLC
    2.63M3.60%
  • Rosalind Advisors, Inc.
    1.53M2.10%
  • DCF Advisers, LLC
    1.43M1.96%
  • Sio Capital Management, LLC
    1.30M1.78%
  • Morgan Stanley - Brokerage Accounts
    1.03M1.40%
  • Nan Fung Group Holdings Ltd
    987.22K1.35%
  • Sphera Funds Management Ltd.
    987.09K1.35%
  • Logos Global Management LP
    750.00K1.03%
  • Boxer Capital Management, LLC
    640.00K0.88%
  • Citadel Advisors Llc
    620.96K0.85%
  • Dafna Capital Management LLC
    514.06K0.70%
  • Knott David M Jr
    370.00K0.51%
  • AdvisorShares Investments, LLC
    292.71K0.40%
  • UBS Group AG
    238.30K0.33%

Top Fund Holders

  • Biotech Growth Ord
    1.01M1.38%
  • SEB Läkemedelsfond A (SEK)
    763.77K1.05%
  • AdvisorShares Psychedelics ETF
    367.43K0.50%

Stock Splits

  • Sep 19, 20241:38
  • Nov 10, 2020149:1000